OncoMatch

OncoMatch/Clinical Trials/NCT06547528

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Is NCT06547528 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ONO-4685 for relapsed or refractory t cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Phase 1RecruitingOno Pharmaceutical Co. LtdNCT06547528Data as of May 2026

Treatment: ONO-4685A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Check if I qualify

Extracted eligibility criteria

Cancer type

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify